Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04128007
Other study ID # ARQ-154-204
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date January 13, 2020
Est. completion date September 25, 2020

Study information

Verified date October 2022
Source Arcutis Biotherapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will assess the safety and efficacy of ARQ-154 foam vs placebo applied once a day for 56 days by subjects with scalp and body psoriasis


Description:

This is a parallel group, double blind, vehicle-controlled study in which ARQ-154 foam or vehicle is applied once daily x 8 weeks to adolescent and adult subjects with scalp and body psoriasis


Recruitment information / eligibility

Status Completed
Enrollment 304
Est. completion date September 25, 2020
Est. primary completion date September 23, 2020
Accepts healthy volunteers No
Gender All
Age group 12 Years and older
Eligibility Inclusion Criteria: - Participants legally competent to read, write, sign and give informed consent, or, in the case of adolscents, assent with consent of a parent(s) or legal guardian, as required by local laws. - Males and females ages 12 years and older (inclusive) at the time of consent for assent (for adolescents). - Scalp psoriasis with an Investigator Global Assessment of Scalp disease severity (S-IGA) of at least Mild ('2') at Baseline. - A Psoriasis Scalp Severity Index (PSSI) score of at least 6 at Baseline. - A PASI score of at least 2 (excluding the palms and soles) at Baseline. - Clinical diagnosis of psoriasis vulgaris of at least 6 months duration as determined by the Investigator. Stable disease for the past 4 weeks. - Females of childbearing potential (FOCBP) must have a negative serum pregnancy test at Screening (Visit 1) and a negative urine pregnancy test at Baseline (Visit 2). - Females of non-childbearing potential must either be post-menopausal with spontaneous amenorrhea for at least 12 months or have undergone surgical sterilization. - Subjects in good health as judged by the Investigator, based on medical history, physical examination, vital signs, serum chemistry labs, hematology values, and urinalysis. - Subjects are considered reliable and capable of adhering to the Protocol and visit schedule according to the Investigator judgment. Exclusion Criteria: - Subjects who cannot discontinue medications and treatments prior to the Baseline visit and during the study according to Excluded Medications and Treatments. - Planned excessive exposure of treated area(s) to either natural or artificial sunlight, tanning bed or other LED. - Subjects currently taking lithium or antimalarial drugs. - Planned initiation or changes to concomitant medication that could, in the opinion of the Investigator, affect psoriasis vulgaris (e.g. beta blockers, ACE inhibitors). - Current diagnosis of non-plaque forms of psoriasis (e.g., guttate, erythrodermic/exfoliative, palmoplantar only involvement, or pustular psoriasis). Current diagnosis of drug-induced psoriasis. - Subjects with any condition on the treatment area which, in the opinion of the Investigator, could confound efficacy measurements. - Known allergies to excipients in ARQ-154. - Subjects who cannot discontinue the use of strong P-450 cytochrome inhibitors e.g., indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone, saquinavir, suboxone and telithromycin for two weeks prior to the Baseline visit (Visit 2) and during the study. - Subjects who cannot discontinue the use of strong P-450 cytochrome inducers e.g., efavirenz, nevirapine, glucocorticoids, barbiturates (including phenobarbital), phenytoin, rifampin, and carbamazepine for two weeks prior to the Baseline visit (Visit 2) and during the study. - Subjects with PHQ-8 >/= 10 or modified PHQ-A >/= 10 at Screening or Baseline. - Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding. - Subjects with any serious medical condition or laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator. - Subjects with a history of chronic alcohol or drug abuse within 6 months of initiation of the investigational product. - Subjects with a history of a major surgery within 4 weeks prior to Baseline (Visit 2) or has a major surgery planned during the study. - Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation. - Current or a history of cancer within 5 years with the exception of fully treated skin basal cell carcinoma, cutaneous squamous cell carcinoma or carcinoma in situ of the cervix. - Subjects with active infection that required oral or intravenous administration of antibiotics, antifungal, or antiviral agents within 7 days of Baseline/Day 0. - Subjects who are family members of the clinical study site, clinical study staff, or sponsor, or family members residing in the same household of enrolled subjects.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Roflumilast foam 0.3%
experimental
Vehicle foam
experimental

Locations

Country Name City State
Australia Arcutis Biotherapeutics Clinical Site 50 East Melbourne Victoria
Australia Arcutis Biotherapeutics Clinical Site 54 Hectorville South Australia
Australia Arcutis Biotherapeutics Clinical Site 51 Kogarah New South Wales
Australia Arcutis Biotherapeutics Clinical Site 52 Westmead New South Wales
Bulgaria Arcutis Biotherapeutics Clinical Site 11 Pleven
Bulgaria Arcutis Biotherapeutics Clinical Site 13 Sevlievo
Bulgaria Arcutis Biotherapeutics Clinical Site 10 Sofia
Bulgaria Arcutis Biotherapeutics Clinical Site 14 Sofia
Bulgaria Arcutis Biotherapeutics Clinical Site 12 Stara Zagora
Canada Arcutis Biotherapeutics Clinical Site 61 Barrie Ontario
Canada Arcutis Biotherapeutics Clinical Site 64 Calgary Alberta
Canada Arcutis Biotherapeutics Clinical Site 60 London Ontario
Canada Arcutis Biotherapeutics Clinical Site 66 Montréal Quebec
Canada Arcutis Biotherapeutics Clinical Site 62 Peterborough Ontario
Canada Arcutis Biotherapeutics Clinical Site 63 Waterloo Ontario
Canada Arcutis Biotherapeutics Clinical Site 65 Westmount Quebec
United States Arcutis Biotherapeutics Site 70 Arlington Texas
United States Arcutis Biotherapeutics Clinical Site 76 Austin Texas
United States Arcutis Biotherapeutics Clinical Site 96 Bexley Ohio
United States Arcutis Biotherapeutics Clinical Site 91 Boynton Beach Florida
United States Arcutis Biotherapeutics Clinical Site 80 Broomall Pennsylvania
United States Arcutis Biotherapeutics Clinical Site 86 College Station Texas
United States Arcutis Biotherapeutics Clinical Site 20 Coral Gables Florida
United States Arcutis Biotherapeutics Clinical Site 79 Covington Louisiana
United States Arcutis Biotherapeutics Clinical Site 21 Cromwell Connecticut
United States Arcutis Biotherapeutics Clinical Site 72 Fremont California
United States Arcutis Biotherapeutics Clinical Site 73 Fridley Minnesota
United States Arcutis Biotherapeutics Clinical Site 87 High Point North Carolina
United States Arcutis Biotherapeutics Clinical Site 74 Houston Texas
United States Arcutis Biotherapeutics Clinical Site 78 Indianapolis Indiana
United States Arcutis Biotherapeutics Clinical Site 77 Louisville Kentucky
United States Arcutis Biotherapeutics Clinical Site 94 Metairie Louisiana
United States Arcutis Biotherapeutics Clinical Site 88 Miami Florida
United States Arcutis Biotherapeutics Clinical Site 90 Miami Florida
United States Arcutis Biotherapeutics Clinical Site 97 Murfreesboro Tennessee
United States Arcutis Biotherapeutics Clinical Site 81 Norfolk Virginia
United States Arcutis Biotherapeutics Clinical Site 89 Pflugerville Texas
United States Arcutis Biotherapeutics Clinical Site 95 Plainfield Indiana
United States Arcutis Biotherapeutics Clinical Site 82 Portland Oregon
United States Arcutis Biotherapeutics Clinical Site 98 Portsmouth New Hampshire
United States Arcutis Biotherapeutics Clinical Site 75 Richmond Virginia
United States Arcutis Biotherapeutics Clinical Site 71 Rogers Arkansas
United States Arcutis Biotherapeutics Clinical Site 99 Rolling Meadows Illinois
United States Arcutis Biotherapeutics Clinical Site 84 Saint Joseph Missouri
United States Arcutis Biotherapeutics Clinical Site 93 San Antonio Texas
United States Arcutis Biotherapeutics Clinical Site 85 San Diego California
United States Arcutis Biotherapeutics Clinical Site 83 Sweetwater Florida

Sponsors (1)

Lead Sponsor Collaborator
Arcutis Biotherapeutics, Inc.

Countries where clinical trial is conducted

United States,  Australia,  Bulgaria,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Achieving Success in the Scalp Investigator Global Assessment (S-IGA) Scale The number of participants achieving success in the S-IGA scale is presented for each arm. Success is defined as an S-IGA score of 0 ('clear') or 1 ('almost clear'), plus a 2-grade improvement from baseline.The S-IGA is 5-point scale assessing the severity of plaque psoriasis on the scalp, with scores ranging from 0 ('clear') to 4 ('severe'). Higher scores indicate greater symptom severity. Week 8
Secondary Number of Participants Achieving Body Investigator Global Assessment (B-IGA) Success at Week 8 The number of participants achieving success in the B-IGA scale is presented for each arm. Success is defined as a B-IGA score of 0 ('clear') or 1 ('almost clear'), plus a 2-grade improvement from baseline. The B-IGA is 5-point scale assessing the severity of plaque psoriasis on the body, with scores ranging from 0 ('clear') to 4 ('severe'). Higher scores indicate greater symptom severity. Week 8
Secondary Number of Participants Achieving Success in Scalp Itch Numerical Rating Scale (SI-NRS) Score The number of participants with a baseline SI-NRS score =4 who achieve success (a =4-point improvement from Baseline) at Weeks 2, 4, and 8 is presented for each arm. The SI-NRS is a participant-reported rating of severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ('no itch') to 10 ('worst imaginable itch'), with higher scores indicating greater symptom severity. Results are based on observed data only. Baseline and Weeks 2, 4, 8
Secondary Change From Baseline in Psoriasis Symptoms Diary (PSD) Score The change from baseline in total PSD scores at Weeks 4 and 8 is presented for each arm. The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity. Baseline and Weeks 4 and 8
Secondary Time to Achieve a 50% Reduction From Baseline in Psoriasis Scalp Severity Index (PSSI-50) Score The time to achieve PSSI-50 (i.e., a 50% reduction from baseline in PSSI score) is presented for each arm. The PSSI measures the extent of psoriasis involvement and the severity of erythema, induration, and desquamation of the scalp. Involvement and severity of psoriasis for the PSSI is scored using a scale of 0 to 72, where 0 = no psoriasis and higher scores indicating greater symptom severity. Results are based on observed data only. Up to 8 weeks
Secondary Number of Participants Achieving Psoriasis Scalp Severity Index-75 (PSSI-75) The number of participants achieving a 75% reduction in PSSI score (i.e., PSSI-75) from baseline. The PSSI measures the extent of psoriasis involvement and the severity of erythema, induration, and desquamation of the scalp. Involvement and severity of psoriasis for the PSSI is scored using a scale of 0 to 72, where 0 = no psoriasis and higher scores indicate greater symptom severity. Results are based on observed data only. Week 8
Secondary Number of Participants Achieving PSSI-90 The number of participants achieving a 90% reduction from baseline PSSI score (i.e., PSSI-90) is presented for each arm. The PSSI measures the extent of psoriasis involvement and the severity of erythema, induration, and desquamation of the scalp. Involvement and severity of psoriasis for the PSSI is scored using a scale of 0 to 72, where 0 = no psoriasis and higher scores indicate greater symptom severity. Results are based on observed data only. Baseline and Week 8
See also
  Status Clinical Trial Phase
Completed NCT01194219 - Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis Phase 3
Recruiting NCT06030076 - A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
Completed NCT04263610 - Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy Phase 4
Completed NCT02601469 - Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis Phase 2
Completed NCT05600036 - A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis Phase 2
Completed NCT05375955 - A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. Phase 2
Completed NCT03614078 - A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis Phase 2
Not yet recruiting NCT05036889 - A 16-week Randomized Evaluation of the Impact of Mind.Px Application on Response to Biologic Treatment in Patients Suffering From Plaque Psoriasis Through Clinical Utility and Health Outcomes. N/A
Completed NCT04603027 - A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis Phase 2
Completed NCT03638258 - The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis Phase 2
Completed NCT02881346 - Efficacy and Tolerability of Enstilar® in Daily Practice
Recruiting NCT02611349 - Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis Phase 3
Completed NCT02251678 - Evaluate the Effect of Elimune Capsules Phase 1
Completed NCT01987843 - Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis Phase 2
Terminated NCT01708629 - Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects Phase 3
Completed NCT01230138 - Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis Phase 2
Withdrawn NCT00747032 - To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis Phase 3
Completed NCT00581100 - Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis Phase 4
Suspended NCT01228656 - Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate Phase 2
Completed NCT00540618 - A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis Phase 2